This case study is presented for educational and professional portfolio demonstration purposes. While inspired by real-world pharmaceutical capital programmes in Ireland, all financial figures, timelines, and operational specifics have been anonymised or adjusted.
No proprietary, confidential or commercially sensitive information is disclosed.